Appendix 1. Characteristics of Study Participants Stratified by Gestational Age							
		<7 weeks of Gestation			7-10 weeks of Gestation		
		Oxycodone	Placebo		Oxycodone	Placebo	
		n=48	n=48	P	n=38	n=38	P
Age in years	Mean \pm SD	27 ± 6	27 ± 7		28 ± 6	27 ± 7	
	Range	18-39	18-39	.74	18-44	18-40	.58
Race/Ethnicity	White/Non- Hispanic	56% (27)	56% (27)		66% (25)	37% (14)	
	Other	44% (21)	44% (21)	1.00	34% (13)	63% (24)	.01
Parity	Nulliparous	40 % (19)	40% (19)		37% (14)	42% (16)	
	Multiparous	60 %(29)	60 %(29)	1.00	63% (24)	58% (22)	.63
Prior vaginal deliv	veries	40% (19)	48% (23)	.41	45% (17)	47% (18)	.82
Prior cesarean deliveries		6% (3)	8% (4)	.69	8% (3)	5% (2)	.64
Prior medical abortions		23% (11)	23% (11)	1.00	29% (11)	16% (6)	.16
Prior surgical abo	Prior surgical abortions		11% (5)	.75	29% (11)	26% (10)	.79
BMI (kg/m ²)		27 ± 6	30 ± 9	.11	28 ±7	26 ± 6	.18
Education	High School or less College	23% (11)	33% (16)		24% (9)	37% (14)	
	(any)	77% (37)	67% (32)	.26	76% (29)	63% (24)	.21
Gestation age in days (Mean ± SD)		41 ± 4	41 ± 5	.37	55 ± 6	57 ± 5	.20

Appendix 2. Characteristics of Participants in the Per Protocol Group				
		Oxycodone (n=57)	Placebo (n=64)	P
Age (years)	Mean ± SD	26.70 ± 5.92	26.73 ± 6.52	
	Range	18-40	19-40	.97
Race/Ethnicity	Other White/Non-	22 (38.6%)	32 (50%)	
	Hispanic	35 (61.4%)	32 (50%)	.21
	High School or			
Education	less	17 (29.82%)	20 (31.25%)	
	College (any)	40 70.18%)	44 (68.75%)	.86
BMI	Mean \pm SD	28.60 ± 6.45	27.02 ± 7.09	
	Range	18.65-48.19	17.00-51.57	.20
Parity	Nulliparous	21 (36.84%)	28 (43.75%)	
•	Multiparous	36 (63.16%)	36 (56.25%)	.44
Prior vaginal deliveries		26 (45.61%)	28 (43.75%)	.84
Prior caesare	an deliveries	4 (7.02%)	5 (7.81%)	.87
Prior medical	labortions	16 (28.07%)	13 (20.31%)	.32
Prior surgical abortions		12 (21.05%)	12 (18.75%)	.75
Prior miscarriages		9 (15.79%)	14 21.88%)	.39
Gestational age				
(Days)	Mean \pm SD	47.56 ± 9.06	48.68 ± 8.62	
	Range	33-67	33-67	.48

	<7weeks of Gestation			7-10 weeks Gestation		
	Oxycodone (n=33)	Placebo (n=34)	P	Oxycodone (n=24)	Placebo (n=30)	P
Maximum Pain Score						
Median*	8 4-10	8 4-10		9	8	
Range	. 10	. 10	.94	2-10	4-10	.40
Duration of Maximum						
Pain (hours) Median*	1.5	1.5		2	.92	
Range	(.08-10)	(.17-12)	.67	(.33-10)	(.02-15)	.14
Reported Max Score >7 (n)	70% (23)	71% (24)	.94	71% (17)	70% (21)	.95
Ibuprofen Tablets Used	7070 (23)	7170 (24)	.,,+	7170 (17)	7070 (21)	.73
Touproten Tablets Osed						
Median*						
	3	3		2	2	
Range	1-9	1-5	.87	1-5	1-7	.67
Filled Adjunctive						
Medication (n)	73% (24)	79% (27)	.52	58% (14)	67% (20)	.53
Used Adjunctive						
Medication (n)	58% (19)	62% (21)	.73	54% (13)	60% (18)	.67
Adjunctive Oxycodone						
Tablets Used						
Median*						
	1	1		1	1	
Range	0-6	0-4	.85	0-6	0-4	.97
Satisfaction with pain						
medications (n)	76% (25)	59% (20)	.14	58% (14)	57% (17)	.9
Presence of Nausea or						
Vomiting (n)	64% (21)	62% (21)	.87	75% (18)	73% (22)	.89
Adequacy of blinding						
(percentage who guessed						
allocation group						
correctly) *11-point Numerical Rating	55% (18)	74% (25)	.03	37% (9)	67% (20)	.58

^{*11-}point Numerical Rating Scale (NRS)

Colwill AC, Bayer L, Bednarek P, Garg B, Jensen JT, Edelman AB. Opioid analgesia for medical abortion: a randomized controlled trial. Obstet Gynecol 2019;134.

Appendix 4. Results of Non-Protocol Followers					
	Oxycodone (n=28)	Placebo (<i>n</i> =21)	P		
Maximum Pain Score	(<i>n</i> -26)	(n-21)			
Median*		_			
Range	6.5 2-10	6 1-10	.73		
Duration of Maximum Pain					
(hours) Median*	.6	.5	.66		
Range	(.02-4)	(.01-6)			
Onset of Worst Pain from					
Misoprostol Administration	2.5 <u>+</u> 1.4	2.9 <u>+</u> 1.7	.32		
(hours <u>+</u> SD)					
Reported Max Score >7 (n)	32% (9)	29% (6)	.79		
Ibuprofen Tablets Used					
Median*					
_	2	2			
Range	0-4	0-4	.99		
Filled Adjunctive Medication	14% (4)	29% (6)	.22		
(n)	` '	. ,			
Used Adjunctive Medication	7% (2)	10% (2)	.76		
(n) Adjunctive Oxycodone Tablets					
Use					
Ose					
Median*					
	0	0			
Range	0-2	0-5	.72		
Satisfaction with pain	(10/ (17)		25		
medications (n)	61% (17)	76% (16)	.25		
Presence of Nausea or	57% (16)	33% (7)	.09		
Vomiting (n)	, ,	33% (7)	.09		
*11-point Numerical Rating Scale (NRS)				

Appendix 5. Cha	aracteristics of Prot	ocol Versus Non-pro	otocol Followers	
		Protocol Followers (n=121)	Non-protocol Followers (n=49)	P
Age (years)	$Mean \pm SD$	26.7 ± 6.2	28.5 ± 6.6	.09
Race/Ethnicity	Other White/Non-	54 (44.6%)	24 (49.0%)	
	Hispanic	67 (55.4%)	25 (51.0%)	.61
Education	High School or less College (any)	37 (30.6%) 83 (68.6%)	13 (26.5%) 36 (73.5%)	.70
BMI	Mean	25.5	25.6	.,,
	Range	16.3-60.2	16.9-48.2	.57
Parity	Nulliparous Multiparous	49 (40.5%) 72 (59.5%)	18 (36.7%) 31 (63.3%)	.65
Prior vaginal	deliveries	54 (44.6%)	23 (46.9%)	.78
Prior caesarea	an deliveries	9 (7.4%)	3 (6.1%)	.76
Prior medical	abortions	29 (24.0%)	10 (20.4%)	.62
Prior surgical abortions		24 (19.8%)	7 (14.3%)	.40
Prior miscarriage	es .	23 (19.0%)	11 (22.5%)	.61
Gestational age (Days)	Mean \pm SD	48.2 ± 8.8	46.2 ± 8.9	.19

	Protocol Followers (n=121)	Non-protocol Followers (n=49)	P
Maximum Pain Score			
Median*	8	6	۰.01
Range Duration of Maximum Pain	2-10	1-10	<.01
(hours) Median* Range	2 (.02-15)	.5 (.01-6)	<.01
Onset of Worst Pain from Misoprostol Administration (hours <u>+</u> SD)	2.3 ± 1.5	2.7 <u>+</u> 1.5	.22
Reported Max Score >7 (n)	70% (85)	31% (15)	<.01
Ibuprofen Tablets Used			
Median*	2	2	. 01
Range Filled Adjunctive Medication (n)	1-9 70% (85)	0-4 20% (10)	<.01
Used Adjunctive Medication (n)	59% (71)	8% (4)	<.01
Adjunctive Oxycodone Tablets Used			
Median* Range	0 0-2	0 0-5	.72
Satisfaction with pain medications (n)	63% (76)	67% (33)	.58
Presence of Nausea or Vomiting (n)	68% (82)	47% (23)	.01